SEC Form 4 · accession 0001209191-18-047483
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ilise Lombardo
Officer — Chief Medical Officer
Period of report
Aug 15, 2018
Accepted (ET)
Aug 17, 2018 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $2.02 | Aug 15, 2018 | A | 100,000 | A | — | Aug 14, 2028 | Common Shares | 100,000 | 100,000 | D |
Explanation of responses
- F1One-third of the option will vest at such time as the Issuer's stock price is equal to $6.06; one-third of the option will vest at such time as the Issuer's stock price is equal to $10.10; and one-third of the option will vest at such time as the Issuer's stock price is equal to $14.14, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date.
- F2The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.